

EXECUTIVE/PERSONNEL COMMITTEE MEETING  
BOARD OF TRUSTEES  
THE METROHEALTH SYSTEM  
March 9, 2016

Committee Members Present: Mr. McDonald, Mr. Monnolly, Dr. Silvers, Ms. Whiting

Additional Trustees Present: Ms. Dee, Rev. Minor, Mr. Moss, Mr. Schneider, Mr. Spain

Staff Present: Dr. Boutros, Ms. Allen, Ms. Bechtle, Mr. Botros, Dr. Boulanger,  
Ms. Jacono, Mr. Jones, Mr. Lewis, Dr. Perzy, Mr. Phillips (via phone),  
Ms. Rajki, Mr. Richmond

Mr. McDonald called the meeting to order at approximately 8:00 a.m.

The minutes for the meeting of February 10, 2016, were approved as submitted.

Introduction of Dr. Boulanger

Dr. Boutros introduced Dr. Boulanger as the new Chief Clinical Officer. Dr. Boulanger told the Board members about his background as a trauma surgeon and prior positions. He said that he was glad to be joining The MetroHealth System.

Comparative Influenza Statistics

Dr. Boulanger gave a report to the Committee members on the recent influenza statistics. He reported that cases of influenza were lower than the prior year largely due to the efficacy of the flu vaccine. The flu vaccine was 60% effective this year, versus 20% effective last year. What MetroHealth is experiencing is similar to other local institution's experience with influenza.

2016 Goals

Mr. McDonald led a discussion about the 2016 System wide goals and measures. Dr. Boutros gave the Committee background on the budget and how the financial target goals are set. The draft 2016 goals and measures were reviewed. The Committee discussed multiple issues relating to the financial goals, the various matters which may impact System financial results, and the terms and objectives of the performance-based variable compensation structure. After discussion, it was agreed that the draft goals would be adjusted in the areas of the financial targets and the content of the Community and Diversity goal and then be presented to the Board for approval at its regular March meeting.

Executive Session

Upon unanimous roll call vote, the Committee went into Executive Session to discuss various matters constituting or involving Trade Secrets and pending litigation.

At the end of Executive Session, the Committee reconvened the meeting in open session.

The meeting was adjourned at approximately 10:25 a.m.

Respectfully submitted,

Mr. Thomas M. McDonald  
Chair